(sor-A-feh-nib TOH-suh-layt)
Sorafenib tosylate works by blocking proteins that signal cancer cells to divide. It also blocks proteins that signal the growth of new blood vessels that tumors need to grow. Blocking these signals keeps cancer cells from growing and may kill them. Sorafenib is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily).
FDA label information for this drug is available at DailyMed.
Use in Cancer
Sorafenib tosylate is approved to treat:
- Hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery.
- Renal cell carcinoma (a type of kidney cancer) that is advanced.
- Thyroid cancer in certain patients whose cancer has gotten worse, has come back, or has spread to other parts of the body and did not respond to treatment with radioactive iodine.
Sorafenib tosylate is also being studied in the treatment of other types of cancer.
More About Sorafenib Tosylate
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Sorafenib Tosylate – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Sorafenib Tosylate – Check for trials from NCI’s list of cancer clinical trials now accepting patients.